Improved MECP2 gene therapy extends the survival of MeCP2-null mice without apparent toxicity after intracisternal delivery

Sinnett, S. E., Hector, R. D. , Gadalla, K. K.E. , Heindel, C., Chen, D., Zaric, V., Bailey, M. E.S. , Cobb, S. R. and Gray, S. J. (2017) Improved MECP2 gene therapy extends the survival of MeCP2-null mice without apparent toxicity after intracisternal delivery. Molecular Therapy: Methods and Clinical Development, 5, pp. 106-115. (doi:10.1016/j.omtm.2017.04.006) (PMID:28497072) (PMCID:PMC5424572)

[img]
Preview
Text
139919.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

2MB

Abstract

Intravenous administration of AAV9/hMECP2 has been shown to extend the lifespan of Mecp2-/y mice, but this delivery route induces liver toxicity in wild-type (WT) mice. To reduce peripheral transgene expression, we explored the safety and efficacy of AAV9/hMECP2 injected into the cisterna magna (ICM). AAV9/hMECP2 (1 x 1012 vg; ICM) extended Mecp2-/y survival, but aggravated hindlimb clasping and abnormal gait phenotypes. In WT mice, 1 x 1012 vg of AAV9/hMECP2 induced clasping and abnormal gait. A lower dose mitigated these adverse phenotypes but failed to extend survival of Mecp2-/y mice. Thus, ICM delivery of this vector is impractical as a treatment for Rett syndrome (RTT). To improve the safety of MeCP2 gene therapy, the gene expression cassette was modified to include more endogenous regulatory elements believed to modulate MeCP2 expression in vivo. In Mecp2-/y mice, ICM injection of the modified vector extended lifespan and was well tolerated by the liver, but did not rescue RTT behavioral phenotypes. In WT mice, these same doses of the modified vector had no adverse effects on survival or neurological phenotypes. In summary, we identified limitations of the original vector and demonstrated that an improved vector design extends Mecp2-/y survival without apparent toxicity.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Gadalla, Dr Kamal and Cobb, Dr Stuart and Hector, Dr Ralph and Bailey, Dr Mark
Authors: Sinnett, S. E., Hector, R. D., Gadalla, K. K.E., Heindel, C., Chen, D., Zaric, V., Bailey, M. E.S., Cobb, S. R., and Gray, S. J.
College/School:College of Medical Veterinary and Life Sciences > Institute of Neuroscience and Psychology
Journal Name:Molecular Therapy: Methods and Clinical Development
Publisher:Elsevier
ISSN:2329-0501
ISSN (Online):2329-0501
Published Online:19 April 2017
Copyright Holders:Copyright © 2017 The Authors
First Published:First published in Molecular Therapy: Methods and Clinical Development 5: 106-115
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record